JoVE Logo
Faculty Resource Center

Sign In

Summary

Abstract

Introduction

Protocol

Representative Results

Discussion

Acknowledgements

Materials

References

Medicine

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression

Published: June 28th, 2013

DOI:

10.3791/50395

1Monash Institute of Pharmaceutical Sciences, Monash University, 2Department of Visceral Surgery and Medicine, University of Bern, 3Cousins Center for Neuroimmunology, University of California Los Angeles

Improved understanding of pancreatic cancer biology is critically needed to enable the development of better therapeutic options to treat pancreatic cancer. To address this need, we demonstrate an orthotopic model of pancreatic cancer that permits non-invasive monitoring of cancer progression using in vivo bioluminescence imaging.

Pancreatic cancer has an extremely poor five-year survival rate of 4-6%. New therapeutic options are critically needed and depend on improved understanding of pancreatic cancer biology. To better understand the interaction of cancer cells with the pancreatic microenvironment, we demonstrate an orthotopic model of pancreatic cancer that permits non-invasive monitoring of cancer progression. Luciferase-tagged pancreatic cancer cells are resuspended in Matrigel and delivered into the pancreatic tail during laparotomy. Matrigel solidifies at body temperature to prevent leakage of cancer cells during injection. Primary tumor growth and metastasis to distant organs are monitored following injection of the luciferase substrate luciferin, using in vivo imaging of bioluminescence emission from the cancer cells. In vivo imaging also may be used to track primary tumor recurrence after resection. This orthotopic model is suited to both syngeneic and xenograft models and may be used in pre-clinical trials to investigate the impact of novel anti-cancer therapeutics on the growth of the primary pancreatic tumor and metastasis.

Pancreatic cancer is the fourth leading cause of cancer-related death, with a 5-year survival rate of 4-6%.1,2 Only 15% of patients are diagnosed early enough in the disease to be eligible for surgery, and tumors recur in >80% of those patients.3,4 Gemcitabine is used for treatment of pancreatic adenocarcinomas, however, chemoresistance is common and often the drug has little impact on overall survival.5 New pharmacological strategies to treat pancreatic cancer are critically needed. Their development depends on significantly improved understanding of the key steps of disease progression that may be sensitive to therapeutic....

Log in or to access full content. Learn more about your institution’s access to JoVE content here

The protocol being demonstrated is performed under the guidance and approval of the author's institution's animal care and use committee. All experiments are executed in compliance with all relevant guidelines, regulations and regulatory agencies.

1. Transducing Pancreatic Cancer Cell Lines

  1. Transduce pancreatic cancer cells to express luciferase as previously described.12,13 Panc-1 and Capan-1 pancreatic cancer cell lines transduced with firefly luciferase are used here........

Log in or to access full content. Learn more about your institution’s access to JoVE content here

This method describes an orthotopic model of pancreatic cancer using surgical procedures, including induction of anesthesia, laparotomy, injection of cancer cells in Matrigel and abdominal closure (Figure 1A). The injected cells form a bubble in the surface of the pancreas (Figure 1B). Pancreatic cancer progression may be non-invasively monitored using in vivo bioluminescence imaging to track cancer cell proliferation and dissemination (Figure 2). Liver me.......

Log in or to access full content. Learn more about your institution’s access to JoVE content here

Here we describe an orthotopic model for longitudinal assessment of pancreatic tumor development and progression. Primary tumor growth kinetics are reproducible (Figure 3) and may be non-invasively monitored using bioluminescence imaging of luciferase-tagged cells, e.g. for analyses of tumor response to novel anti-pancreatic cancer therapeutics. Consistent with the human disease, the model shows local pancreatic invasion (Figure 4A) which allows investigation of tumor cel.......

Log in or to access full content. Learn more about your institution’s access to JoVE content here

This work was supported by the National Health and Medical Research Council, Australia (1008865), the Australian Research Council (LE110100125), the National Cancer Institute (CA138687-01), Erica Sloan is supported by an Early Career Fellowship from the National Breast Cancer Foundation, Australia. Corina Kim-Fuchs is supported by a fellowship from the Swiss Cancer League and an HDR scholarship from Monash Institute of Pharmaceutical Sciences. Eliane Angst is supported by a grant from the Bern Cancer League.

....

Log in or to access full content. Learn more about your institution’s access to JoVE content here

Name Company Catalog Number Comments
Equipment Company Catalog Number Comments
Clean Bench coat
Heating pad Set to 37 °C
Ivis Lumina ll Bioluminescent imager Caliper Alternative bioluminescent imaging systems include In vivo F PRO (Carestream) and Photon Imager (Biospace Lab)
Dissecting scissors
Iris forceps (serrated)
Needle holder
27 G 0.3 ml insulin syringe Terumo T35525M2913

  1. American Cancer Society. . Facts and Figures. , (2013).
  2. Hariharan, D., Saied, A., Kocher, H. M. Analysis of mortality rates for pancreatic cancer across the world. HPB (Oxford). 10, 58-62 (2008).
  3. Li, D., Xie, K., Wolff, R., Abbruzzese, J. L. Pancreatic cancer. Lancet. 363, 1049-1057 (2004).
  4. Oettle, H., et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 297, 267-277 (2007).
  5. Andersson, R., et al. Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions. Scand. J. Gastroenterol. 44, 782-786 (2009).
  6. Angst, E., et al. Bioluminescence imaging of angiogenesis in a murine orthotopic pancreatic cancer model. Mol. Imaging Biol. 12, 570-575 (2010).
  7. Angst, E., et al. N-myc downstream regulated gene-1 expression correlates with reduced pancreatic cancer growth and increased apoptosis in vitro and in vivo. Surgery. 149, 614-624 (2011).
  8. Hotz, H. G., et al. An orthotopic nude mouse model for evaluating pathophysiology and therapy of pancreatic cancer. Pancreas. 26, 89-98 (2003).
  9. Partecke, L. I., et al. A syngeneic orthotopic murine model of pancreatic adenocarcinoma in the C57/BL6 mouse using the Panc02 and 6606PDA cell lines. Eur. Surg. Res. 47, 98-107 (2011).
  10. Hingorani, S. R., et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 4, 437-450 (2003).
  11. Sloan, E. K., et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res. 70, 7042-7052 (2010).
  12. Wang, X., McManus, M. Lentivirus production. J. Vis. Exp. (32), e1499 (2009).
  13. Morizono, K., et al. Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat. Med. 11, 346-352 (2005).
  14. Saha, D., et al. In vivo bioluminescence imaging of tumor hypoxia dynamics of breast cancer brain metastasis in a mouse model. J. Vis. Exp. (56), e3175 (2011).
  15. Lim, E., et al. Monitoring tumor metastases and osteolytic lesions with bioluminescence and micro CT imaging. J. Vis. Exp. (52), e2775 (2011).
  16. Burton, J. B., et al. Adenovirus-mediated gene expression imaging to directly detect sentinel lymph node metastasis of prostate cancer. Nat Med. 14, 882-888 (2008).
  17. Vezeridis, M. P., Doremus, C. M., Tibbetts, L. M., Tzanakakis, G., Jackson, B. T. Invasion and metastasis following orthotopic transplantation of human pancreatic cancer in the nude mouse. J. Surg. Oncol. 40, 261-265 (1989).
  18. Fu, X., Guadagni, F., Hoffman, R. M. A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc. Natl. Acad. Sci. U.S.A. 89, 5645-5649 (1992).
  19. Reyes, G., et al. Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice. Cancer Res. 56, 5713-5719 (1996).
  20. Kim, M. P., et al. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc. 4, 1670-1680 (2009).
  21. Furukawa, T., Kubota, T., Watanabe, M., Kitajima, M., Hoffman, R. M. A novel "patient-like" treatment model of human pancreatic cancer constructed using orthotopic transplantation of histologically intact human tumor tissue in nude mice. Cancer Res. 53, 3070-3072 (1993).
  22. Lewis, C. E., Pollard, J. W. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 66, 605-612 (2006).
  23. Brembeck, F. H., et al. The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice. Cancer Res. 63, 2005-2009 (2003).

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved